Enoxaparin Concept

subject area of

• A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients  Academic Article
• A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis  Academic Article
• A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease  Academic Article
• A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis  Academic Article
• A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement  Academic Article
• A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty  Academic Article
• A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery  Academic Article
• A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery  Academic Article
• A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.  Academic Article
• A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment  Academic Article
• A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.  Academic Article
• A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.  Academic Article
• A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin  Academic Article
• A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)  Academic Article
• A simple, readily available method for risk stratification of patients with unstable angina and non-ST elevation myocardial infarction  Academic Article
• Abelacimab for Prevention of Venous Thromboembolism  Academic Article
• American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19  Academic Article
• Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors  Academic Article
• Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization  Academic Article
• Anticoagulant Effect at the Time of Epidural Catheter Removal in Patients Receiving Twice-daily or Once-daily Low-molecular-weight Heparin and Continuous Epidural Analgesia after Orthopedic Surgery  Academic Article
• Anticoagulants in acute coronary syndromes  Academic Article
• Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non–ST-Segment Elevation Acute Coronary Syndromes  Academic Article
• Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin  Academic Article
• Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement  Academic Article
• Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients  Academic Article
• Apixaban versus Enoxaparin in Medically Ill Patients  Academic Article
• Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial  Academic Article
• Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial  Academic Article
• Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery  Academic Article
• BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study  Academic Article
• Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty  Academic Article
• Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT)  Academic Article
• Brief Communication: Preoperative Anticoagulant Activity after Bridging Low-Molecular-Weight Heparin for Temporary Interruption of Warfarin  Academic Article
• Can we differentiate the low-molecular-weight heparins?  Academic Article
• Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial  Academic Article
• Ciraparantag for enoxaparin reversal: Adding to the evidence  Academic Article
• Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo  Academic Article
• Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin  Academic Article
• Clinical trials of deep vein thrombosis prophylaxis in medical patients  Academic Article
• Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - A direct and selective antagonist  Academic Article
• Comparison Of The Relative Efficacy And Safety Of Low Molecular Weight Heparin And Unfractionated Heparin For The Treatment Of Venous Thrombosis  Conference Paper
• Comparison of Effectiveness of Enoxaparin Versus Unfractionated Heparin to Reduce Silent and Clinically Apparent Acute Myocardial Infarction in Patients Presenting With Non–ST-Segment Elevation Acute Coronary Syndrome  Academic Article
• Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy  Academic Article
• Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes  Academic Article
• Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins  Academic Article
• Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)-5 trial  Academic Article
• Correlation of Plasma Coagulation Parameters With Thromboprophylaxis, Patient Characteristics, and Outcome in the MEDENOX Study  Academic Article
• Cost prediction models for the comparison of two groups  Academic Article
• Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.  Academic Article
• Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis  Academic Article
• Dabigatran etexilate for prevention of venous thromboembolism  Academic Article
• Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3)  Academic Article
• Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)–5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non–ST-segment elevation acute coronary syndromes  Academic Article
• Differences in the safety profiles of two low-molecular-weight heparins  Academic Article
• Dose Capping Enoxaparin Is Unjustified and Denies Patients With Acute Coronary Syndromes a Potentially Effective Treatment  Academic Article
• Dosing Practices and Risk Factors for Bleeding in Patients Receiving Enoxaparin for the Treatment of an Acute Coronary Syndrome  Academic Article
• ESSENCE trial results: breaking new ground. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events.  Academic Article
• Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy  Academic Article
• Economic Evaluation of the MEDENOX Trial: A Canadian Perspective  Academic Article
• Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review  Academic Article
• Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].  Academic Article
• Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial  Academic Article
• Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty  Academic Article
• Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis  Academic Article
• Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines  Academic Article
• Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention  Academic Article
• Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment  Academic Article
• Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction  Academic Article
• Enoxaparin Use in the Neonatal Intensive Care Unit: Experience Over 8 Years  Academic Article
• Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty  Academic Article
• Enoxaparin for neonatal thrombosis: A call for a higher dose for neonates  Academic Article
• Enoxaparin plus Compression Stockings Compared with Compression Stockings Alone in the Prevention of Venous Thromboembolism after Elective Neurosurgery  Academic Article
• Enoxaparin versus Unfractionated Heparin in ST-Elevation Myocardial Infarction  Academic Article
• Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.  Academic Article
• Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility  Academic Article
• Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: Methodology for the EXCLAIM study  Academic Article
• Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis  Academic Article
• Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism  Academic Article
• Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates  Academic Article
• Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery  Academic Article
• Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture Surgery  Academic Article
• Fondaparinux Reduces Long-term Risk of Venous Thromboembolism After Surgery for Hip Fractur  Academic Article
• Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk  Academic Article
• Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6  Academic Article
• Fondaparinux versus Enoxaparin in non–ST-elevation acute coronary syndromes: Short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial  Academic Article
• Fondaparinux versus enoxaparin for prevention of venous thromboembolism  Academic Article
• Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic SurgeryA Meta-analysis of 4 Randomized Double-blind Studies  Academic Article
• Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin  Academic Article
• Idrabiotaparinux treatment for venous thromboembolism  Academic Article
• Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients  Academic Article
• Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction  Academic Article
• Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes  Academic Article
• In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation  Academic Article
• Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non–ST-Segment Elevation Acute Coronary Syndromes  Academic Article
• Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes  Academic Article
• Less menorrhagia for women with VTE  Academic Article
• Letter to the editor  Academic Article
• Low Molecular Weight Heparin Administered once versus twice Daily in Patients with Venous Thromboembolism  Academic Article
• Low molecular weight heparins in the treatment of unstable angina.  Academic Article
• Low-Molecular-Weight Heparin as an Adjunct to Thrombolysis in ST Elevation Myocardial Infarction  Academic Article
• Low-Molecular-Weight Heparins  Academic Article
• Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.  Academic Article
• Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting  Academic Article
• Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B.  Academic Article
• Management of unstable angina and myocardial infarction  Academic Article
• Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides  Academic Article
• Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo  Academic Article
• Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency  Academic Article
• Minimizing costs for treating deep vein thrombosis: the role for fondaparinux  Academic Article
• Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound1  Academic Article
• Optimizing Prophylaxis of Venous Thromboembolism  Academic Article
• Oral Apixaban for the Treatment of Acute Venous Thromboembolism  Academic Article
• Oral Rivaroxaban for Symptomatic Venous Thromboembolism  Academic Article
• Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism  Academic Article
• Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial  Academic Article
• Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement  Academic Article
• Overview of the clinical results of pentasaccharide in major orthopedic surgery.  Academic Article
• Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial  Academic Article
• Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison  Academic Article
• Preoperative Enoxaparin Versus Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery  Academic Article
• Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes.  Academic Article
• Prevention of venous thromboembolism in medical patients with enoxaparin  Academic Article
• Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)  Academic Article
• Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease∗∗∗∗A list of participating ESSENCE Study Group investigators may be found in N Engl J Med 1997;337:447–52.  Academic Article
• Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes  Academic Article
• Reversal of anti-thrombin activity using protamine sulfate. Experience in a neonate with a 10-fold overdose of enoxaparin  Academic Article
• Review of enoxaparin and its clinical applications in venous and arterial thromboembolism  Academic Article
• Risk Factors for Venous Thromboembolism in Hospitalized Patients With Acute Medical Illness  Academic Article
• Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty  Academic Article
• Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies  Academic Article
• Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty  Academic Article
• Rivaroxaban versus enoxaparin after total knee arthroplasty  Academic Article
• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial  Academic Article
• SR123781A: A New Once-Daily Synthetic Oligosaccharide Anticoagulant for Thromboprophylaxis After Total Hip Replacement Surgery  Academic Article
• Selective factor Xa inhibition for thromboprophylaxis  Academic Article
• Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE  Academic Article
• Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review  Academic Article
• Superiority of Fondaparinux Over Enoxaparin in Preventing Venous Thromboembolism in Major Orthopedic Surgery Using Different Efficacy End Points  Academic Article
• The Editor's Roundtable: Arterial Thrombosis and Acute Coronary Syndromes  Academic Article
• The Incidence of Symptomatic Venous Thromboembolism After Enoxaparin Prophylaxis in Lower Extremity Arthroplasty  Academic Article
• The Incidence of Symptomatic Venous Thromboembolism During and After Prophylaxis With EnoxaparinA Multi-institutional Cohort Study of Patients Who Underwent Hip or Knee Arthroplasty  Conference Paper
• The United States Food and Drugs Administration Approves a Generic Enoxaparin  Academic Article
• The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: An evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients  Academic Article
• The design of venous thromboembolism prophylaxis trials: Fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery  Academic Article
• The effects of rivaroxaban on the complications of surgery after total hip or knee replacement  Academic Article
• The use of low molecular weight heparin in pediatric patients: A prospective cohort study  Academic Article
• The use of low molecular weight heparins in pediatrics: Two cases that highlight potential risks to patient safety  Academic Article
• Therapy of unstable angina with the low molecular weight heparins  Academic Article
• Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials  Academic Article
• Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in medical patients with enoxaparin (MEDENOX) trial  Academic Article
• Thrombotic Complications and Thromboprophylaxis Across All Three Stages of Single Ventricle Heart Palliation  Academic Article
• To anticoagulate? Controversy in the management of thrombotic complications of head & neck infections  Academic Article
• Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study  Academic Article
• Use of a single anti-Xa calibration curve is adequate for monitoring enoxaparin and tinzaparin levels in children  Academic Article
• Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients  Academic Article
• Venous Thromboembolism Risk in Ischemic Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Results From the EXCLAIM Study  Academic Article
• Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.  Academic Article
• Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?  Academic Article
• XIX congress of the European Society of Cardiology August 24-28, 1997, Stockholm, Sweden.  Conference Paper
• [Prevention of thrombosis among medical inpatients : should we adapt enoxaparin doses to the patient's weight ?]  Academic Article